捷健康将在ASTRO年度会议上展示FDA批准的Gelclair用于口腔粘膜炎的治疗. Jaguar Health to present FDA-approved Gelclair for oral mucositis management at ASTRO Annual Meeting.

Jaguar Health Inc. 将在华盛顿特区举行的 ASTRO 年会上展示 FDA 批准的口腔粘膜炎产品 Gelclair。Gelclair 帮助管理由化疗和放疗引起的口腔病变，缓解疼痛并提高患者的饮食能力。 Jaguar Health Inc. will showcase Gelclair, an FDA-approved product for oral mucositis, at the ASTRO Annual Meeting in Washington, D.C. Gelclair helps manage oral lesions caused by chemotherapy and radiation, offering pain relief and improving patients' ability to eat and drink. 该产品定于2024年10月在美国推出,旨在解决口服肌肉炎问题,这是影响许多癌症患者的一个常见和严重的副作用。 The product, set to launch in the U.S. in October 2024, aims to address oral mucositis, a common and serious side effect affecting many cancer patients.

September 24, 2024

4 文章